Wimmer Associates 1 LLC reduced its holdings in Stryker Corporation (NYSE:SYK) by 8.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,303 shares of the medical technology company’s stock after selling 475 shares during the quarter. Wimmer Associates 1 LLC’s holdings in Stryker were worth $753,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. Renaissance Technologies LLC acquired a new position in shares of Stryker during the 1st quarter valued at $948,000. Altavista Wealth Management Inc. increased its position in shares of Stryker by 0.9% during the 1st quarter. Altavista Wealth Management Inc. now owns 37,371 shares of the medical technology company’s stock valued at $4,920,000 after purchasing an additional 329 shares during the period. First Financial Equity Corporation acquired a new position in shares of Stryker during the 1st quarter valued at $419,000. Bfsg LLC acquired a new position in shares of Stryker during the 1st quarter valued at $1,655,000. Finally, Janus Capital Management LLC increased its position in shares of Stryker by 2.4% during the 1st quarter. Janus Capital Management LLC now owns 1,072,704 shares of the medical technology company’s stock valued at $141,221,000 after purchasing an additional 24,900 shares during the period. Hedge funds and other institutional investors own 74.97% of the company’s stock.
SYK has been the subject of several research reports. Royal Bank Of Canada reissued a “buy” rating and set a $155.00 price objective on shares of Stryker in a research note on Friday, September 1st. Robert W. Baird raised Stryker from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $161.00 to $173.00 in a research note on Thursday, November 16th. Argus reissued a “buy” rating and set a $160.00 price objective on shares of Stryker in a research note on Tuesday, August 29th. Zacks Investment Research lowered Stryker from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Finally, Stifel Nicolaus raised their price objective on Stryker from $158.00 to $168.00 and gave the stock a “buy” rating in a research note on Friday, October 27th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $152.10.
Shares of Stryker Corporation (NYSE SYK) traded down $0.27 during trading on Thursday, hitting $151.76. The stock had a trading volume of 1,090,500 shares, compared to its average volume of 1,181,132. The firm has a market capitalization of $56,895.34, a PE ratio of 24.09, a PEG ratio of 2.39 and a beta of 0.78. The company has a current ratio of 2.37, a quick ratio of 1.61 and a debt-to-equity ratio of 0.63. Stryker Corporation has a 1-year low of $111.22 and a 1-year high of $160.62.
Stryker (NYSE:SYK) last issued its earnings results on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.02. The business had revenue of $3.01 billion during the quarter, compared to analysts’ expectations of $2.97 billion. Stryker had a return on equity of 24.11% and a net margin of 14.67%. Stryker’s revenue was up 6.1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.39 earnings per share. research analysts anticipate that Stryker Corporation will post 6.47 earnings per share for the current fiscal year.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.